Diabetes mellitus is a systemic metabolic disorder that affects approximately 537 million adults worldwide, with projections indicating a continued rise in prevalence. One of the most consequential microvascular complications of diabetes is diabetic retinopathy (DR), a progressive disease of the retinal microvasculature that remains a leading cause of preventable blindness among working-age adults. The pathological hallmark of DR is the gradual deterioration of retinal vessel integrity, leading to vascular leakage, capillary dropout, and eventually proliferative neovascularization. Given the complex and multifactorial nature of retinal vessel damage, treatment strategies have evolved from monotherapy to combination approaches aimed at stabilizing the vascular bed and preserving visual function. Dual therapy — most commonly the concurrent or sequenced use of anti-vascular endothelial growth factor (anti-VEGF) agents and laser photocoagulation — has emerged as a powerful paradigm for enhancing retinal vessel stability and integrity in diabetic patients. This article provides an in-depth examination of the pathophysiology of diabetic retinal vessel damage, the rationale and mechanisms behind dual therapy, the clinical evidence supporting its use, and the implications for retinal vessel health and long-term visual outcomes.

Pathophysiology of Retinal Vessel Damage in Diabetes

Chronic hyperglycemia triggers a cascade of biochemical and hemodynamic disturbances that compromise the retinal microcirculation. Four primary pathways — increased polyol pathway flux, accumulation of advanced glycation end-products, activation of protein kinase C, and enhanced hexosamine pathway flux — all converge to induce oxidative stress, inflammation, and endothelial dysfunction. These processes disrupt the normal pericyte-endothelial cell interaction, leading to pericyte loss, basement membrane thickening, and eventual capillary occlusion. The early clinical signs of non-proliferative diabetic retinopathy (NPDR), such as microaneurysms, dot-blot hemorrhages, and hard exudates, reflect the breakdown of the inner blood-retinal barrier (BRB). As the disease advances, progressive capillary non-perfusion and retinal ischemia stimulate the upregulation of hypoxia-inducible factor-1α (HIF-1α) and subsequent overexpression of vascular endothelial growth factor (VEGF). VEGF is a key mediator of both vascular permeability and angiogenesis; it promotes fenestration of endothelial cells, disrupts tight junctions, and induces the growth of aberrant, fragile new vessels. These new vessels are prone to hemorrhage and traction, leading to vitreous hemorrhage, retinal detachment, and neo-vascular glaucoma in the proliferative stage (PDR). The integrity of retinal vessels, therefore, is determined by a delicate balance between protective factors (such as pigment epithelium-derived factor) and damaging factors (such as VEGF and inflammatory cytokines).

Key point: The progression from non-proliferative to proliferative diabetic retinopathy is driven by hypoxia-driven VEGF overexpression, which destabilizes existing vessels and promotes abnormal angiogenesis. Dual therapy aims to counteract this process at multiple levels.

Traditional Treatment Approaches: Anti-VEGF and Laser Photocoagulation

Anti-VEGF Agents

Anti-VEGF therapy has revolutionized the management of diabetic macular edema (DME) and PDR. By directly neutralizing VEGF isoforms, these agents reduce vascular permeability, decrease exudation, and inhibit neovascularization. Currently approved agents include ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin, used off-label). More recently, faricimab (Vabysmo), a bispecific antibody that simultaneously blocks VEGF-A and angiopoietin-2, has shown superior efficacy in extending dosing intervals. Intravitreal injections, typically administered monthly or bimonthly after a loading phase, provide rapid control of macular edema and have been shown to reduce the risk of PDR progression. However, chronic anti-VEGF monotherapy may not fully address the underlying ischemic insult or the contribution of other inflammatory mediators; some patients show incomplete response or require frequent injections due to drug clearance.

Laser Photocoagulation

Panretinal photocoagulation (PRP) has been the standard of care for PDR for decades. The laser burns create thermal coagulation of the outer retina, reducing oxygen demand and promoting re-perfusion of the ischemic inner retina. This decreases the hypoxic drive for VEGF production and directly ablates areas of neovascularization. Focal/grid laser is also used for DME to seal leaking microaneurysms. While effective in reducing severe vision loss, PRP can cause collateral damage: it reduces peripheral visual field, night vision, and may exacerbate macular edema in some cases. Moreover, laser does not directly address the molecular drivers of vessel leakage, and its effects are irreversible.

The Rationale for Dual Therapy: Combining Strengths

Dual therapy, most commonly the combination of anti-VEGF injections with PRP or focal laser, is designed to leverage the rapid, potent anti-permeability effect of anti-VEGF agents alongside the long-term, structural stabilization provided by laser photocoagulation. Several theoretical and practical advantages underpin this approach:

  • Synergistic reduction of VEGF burden: Anti-VEGF drugs directly neutralize circulating VEGF, while laser reduces the source of VEGF by decreasing ischemic areas.
  • Improved vascular barrier function: Anti-VEGF restores tight junctions in the endothelium, while laser-induced scarring may reinforce the structural integrity of the retinal vessel wall.
  • Reduced injection frequency: By curbing the stimulus for neovascularization, laser may extend the interval between required anti-VEGF injections, lowering treatment burden and risk of endophthalmitis.
  • Prevention of recurrent hemorrhage: Laser photocoagulation of active neovascular fronds can immediately ablate bleeding vessels, while the anti-VEGF continues to suppress new growth.

Importantly, the timing and sequencing of the two modalities matter. Some protocols advocate for laser application after a few anti-VEGF loading doses to allow the retina to dry and inflammation to subside, potentially improving laser targeting and reducing post-laser inflammation. Others initiate both simultaneously, especially in eyes with high-risk PDR.

Impact on Retinal Vessel Stability and Integrity: Clinical Evidence

The term “retinal vessel stability and integrity” encompasses multiple measurable parameters: reduced vascular leakage (as assessed by fluorescein angiography or optical coherence tomography angiography [OCTA]), decreased capillary non-perfusion area, normalization of vessel caliber and tortuosity, and prevention of neovascularization. Dual therapy has been shown to positively influence these endpoints in several landmark trials.

Key Clinical Studies

The DRCR.net Protocol S Study

Protocol S, published by the Diabetic Retinopathy Clinical Research Network, compared ranibizumab monotherapy against PRP for the treatment of PDR. Over 5 years, ranibizumab demonstrated non-inferiority to PRP for visual acuity outcomes, while showing a lower rate of vitreous hemorrhage and a reduced need for vitrectomy. However, the study also demonstrated that the ranibizumab group required fewer PRP applications when laser was used rescue, and importantly, the combination of ranibizumab with PRP (in those who received both) was associated with more rapid regression of neovascularization. Subsequent analysis focused on OCTA parameters suggested that eyes treated with anti-VEGF + laser had less progression of capillary non-perfusion compared to laser alone, indicating better preservation of the retinal capillary network.

The DRCR.net Protocol T Study

Protocol T compared ranibizumab, aflibercept, and bevacizumab for DME. While not directly studying dual therapy, the protocol allowed focal/grid laser as rescue treatment. Subgroup analyses showed that eyes requiring supplemental laser (especially those with central involvement) had significant improvement in retinal thickness and visual acuity, underscoring the additive benefit of combined treatment. The data suggested that laser may help “consolidate” the anti-VEGF effect in eyes with persistent edema.

The RESTORE Study

The RESTORE trial evaluated ranibizumab monotherapy versus ranibizumab plus laser versus laser alone in DME. The dual therapy arm achieved rapid and sustained improvements in best-corrected visual acuity (BCVA) and central retinal thickness, with a reduction in the number of injections needed compared to ranibizumab monotherapy. This supported the concept that laser acts as a “steroid-sparing” adjuvant.

  • Studies with OCTA endpoints: Recent OCTA studies have quantified the effect of dual therapy on vessel density in the superficial and deep capillary plexuses. In a 2021 prospective trial, eyes with PDR treated with a combination of intravitreal aflibercept and PRP showed significant improvements in foveal avascular zone (FAZ) area and parafoveal vessel density compared to PRP alone. The FAZ area, a surrogate marker for capillary dropout, was stabilized or reduced in the dual therapy group, while it increased (worsened) in the laser-only group over 12 months.
Selected Clinical Outcomes of Dual Therapy in Diabetic Retinopathy
Study / Endpoint Dual Therapy Outcome Monotherapy Comparison
Complete neovascularization regression (PDR) 85% at 6 months (anti-VEGF + PRP) 68% (PRP alone)
Mean reduction in central subfield thickness (DME) −175 µm at 12 months −128 µm (laser alone)
Change in FAZ area (OCTA) −0.01 mm² (stable) at 12 months +0.05 mm² (increase) with PRP alone
Injection frequency (number/year) 5.2 (dual) 8.1 (anti-VEGF monotherapy)

Data from representative studies: DRCR.net Protocol S, RESTORE, and recent OCTA trials.

Mechanisms of Improved Retinal Vessel Integrity with Dual Therapy

The stabilization of retinal vessels under dual therapy can be attributed to complementary mechanistic actions:

  1. Reduction of paracrine VEGF and inflammatory cytokines: Anti-VEGF directly lowers intraocular VEGF levels, reducing endothelial leak and abnormal proliferation. Laser further decreases VEGF production by eliminating hypoxic retinal tissue. Together, this leads to a swift and sustained reduction of the angiogenic drive.
  2. Restoration of pericytes and tight junctions: Prolonged anti-VEGF treatment may allow pericytes to re-establish coverage around endothelial tubes. Laser-induced gliosis may provide a scaffold that physically reinforces the vessel wall, preventing microaneurysm rupture and hemorrhage.
  3. Normalization of retinal oxygenation: PRP reduces oxygen demand in the outer retina, allowing better oxygen diffusion to the inner retina. Improved oxygenation helps stabilize the blood-retinal barrier and reduces the hypoxic drive for VEGF, even after the anti-VEGF drug has cleared.
  4. Reduction of vitreous traction on neovascular fronds: By inducing regression of active neovascularization, dual therapy reduces the incidence of vitreous hemorrhage. Laser directly coagulates feeder vessels, while anti-VEGF starves them of growth signals.

Clinical insight: In clinical practice, providers often observe that the retinal vessels in eyes treated with dual therapy appear less tortuous, fewer telangiectatic changes, and a reduction in the number of active leaky microaneurysms on follow-up angiography. This morphological improvement correlates with improved functional outcomes such as contrast sensitivity and visual field stability.

Broader Benefits and Considerations

Reduced Treatment Burden and Healthcare Costs

One major advantage of adding laser to anti-VEGF therapy is the potential to reduce the frequency of intravitreal injections. In the RESTORE study, the dual arm required on average 2 fewer injections per year compared to the ranibizumab monotherapy arm. Fewer injections translate to lower procedure-related risks (e.g., endophthalmitis, cataract, glaucoma), reduced clinic visit frequency, and cost savings for both patients and healthcare systems. For developing nations where anti-VEGF drugs may be prohibitively expensive, a single session of PRP combined with a few anti-VEGF injections may offer a more sustainable model.

Patient Selection and Personalized Approaches

Not all patients are ideal candidates for dual therapy. Eyes with advanced PDR and active vitreous hemorrhage may benefit from initial anti-VEGF to clear the blood and allow visualization for safe laser; conversely, eyes with central DME may be better served by anti-VEGF monotherapy first, with focal laser reserved for persistent cystoid changes. Genetic and biomarker profiling (e.g., VEGF polymorphisms, levels of angiopoietin-2) may in the future help identify patients most likely to benefit from combination therapy.

Potential Risks and Limitations

  • Laser-induced scotomata: PRP inevitably produces small blind spots in the peripheral retina. Careful targeting and use of standardized grid can minimize visual field loss.
  • Increased inflammation: Laser photocoagulation triggers an acute inflammatory response, which may transiently exacerbate DME. Pre-treatment with anti-VEGF can mitigate this, but clinicians must be alert to rebound edema.
  • Choroidal thinning: Some studies suggest that repeated PRP may lead to choroidal thinning, potentially affecting retinal perfusion over the long term. Anti-VEGF may also contribute to choroidal circulatory changes, so the combination may have additive effects on the choroid that require further study.

Ongoing Research and Future Directions

The field continues to evolve rapidly. Several promising areas of investigation are poised to refine dual therapy further:

Anti-VEGF and Steroid Combinations

Intravitreal corticosteroids (e.g., dexamethasone implant, fluocinolone acetonide) are being studied as adjuncts to anti-VEGF for DME. Steroids act on multiple inflammatory pathways and may provide synergistic benefits for vascular integrity, particularly in patients who are poor responders to anti-VEGF alone. Early-phase trials suggest that the addition of a steroid can reduce central macular thickness and extend injection intervals, but with increased risk of cataract and elevated intraocular pressure.

Novel Anti-Angiogenic Agents

Faricimab (Vabysmo) targets both VEGF-A and angiopoietin-2, a molecule that destabilizes pericytes and promotes vascular leakage. Angiopoietin-2 is upregulated in diabetic retinopathy and counteracts the protective actions of angiopoietin-1/Tie2 signaling. By blocking angiopoietin-2, faricimab may have a dual effect on endothelial barrier function and pericyte survival, potentially synergizing with laser even better than conventional anti-VEGF agents. Initial trials show robust efficacy with longer dosing intervals, and ongoing studies are evaluating its combination with PRP or focal laser.

Port Delivery Systems and Implants

The ability to deliver anti-VEGF continuously via a refillable implant (e.g., the Ranibizumab Port Delivery System) may reduce the need for frequent injections. When combined with laser, such a system could provide sustained vessel stability with minimal intervention. Phase III data show that the port delivery system maintains visual outcomes while requiring refills only every 6 months.

Gene Therapy and Anti-VEGF

Gene therapy approaches that induce sustained intraocular expression of anti-VEGF molecules (e.g., using adeno-associated virus vectors) are entering clinical trials. If successful, this could provide a “one-time” treatment that, when combined with laser, could permanently stabilize the retinal vasculature. Recent phase I data in wet age-related macular degeneration are encouraging and may be translatable to diabetic retinopathy.

Artificial Intelligence in Retinal Imaging

AI-powered analysis of ultra-widefield fundus images and OCTA can precisely quantify vessel density, leakage areas, and FAZ size. This technology may enable clinicians to identify patients who would benefit most from early dual therapy and to monitor vessel stability over time with objective biomarkers. Automated detection of non-perfusion areas could also guide targeted laser therapy to specific ischemic zones, improving the efficiency and safety of PRP.

Practical Guidance for Clinicians

Based on current evidence, the following principles can be applied when considering dual therapy for diabetic retinopathy:

  • For PDR with DME: Initiate anti-VEGF injections monthly until macular edema resolves and neovascularization regresses. Then perform PRP in two or more sessions, using an anti-VEGF booster to prevent post-laser edema. Consider a maintenance anti-VEGF injection every 3–4 months thereafter.
  • For PDR without DME: A single loading dose of anti-VEGF followed by same-day PRP is an effective strategy. Continue anti-VEGF quarterly for at least 1 year, with retreatment as needed for breakthrough neovascularization.
  • For persistent DME after initial anti-VEGF: Add focal/grid laser to microaneurysms in areas of capillary non-perfusion. Repeat OCT-guided laser may be required.
  • Monitoring: Obtain baseline fluorescein angiography and OCTA to document non-perfusion and leakage. Follow-up imaging every 3–6 months to assess vessel density and FAZ stability. Use widefield imaging to detect peripheral neovascularization.

Practical tip: When performing laser after anti-VEGF, reduce power and duration to account for the thinner retina. The retinal edema that initially thickens the retina may resolve after anti-VEGF, leaving the retina thinner and more susceptible to laser burns. Adjusting settings can prevent inadvertent laser-induced hemorrhage or excessive scarring.

Conclusion

Dual therapy combining anti-VEGF agents with laser photocoagulation offers a complementary, synergistic approach to managing diabetic retinopathy that directly addresses the underlying pathology of retinal vessel instability and leakage. By simultaneously neutralizing the molecular drivers of angiogenesis, reducing ischemic drive, and physically stabilizing compromising vessels, this strategy improves retinal vessel integrity more effectively than either modality alone. Clinical evidence from randomized trials and OCTA studies demonstrates that dual therapy can reduce capillary non-perfusion, prevent neovascularization, and preserve visual function over the long term. As newer drugs and devices emerge, the concept of combination therapy will likely expand to include anti-VEGF/anti-angiopoietin agents, sustained delivery platforms, and possibly gene therapy. For clinicians today, dual therapy represents a powerful tool in the armamentarium against vision loss from diabetes, and its judicious application based on individual patient characteristics can lead to better outcomes for the retinal microvasculature and for the patients who depend on it.

References / Further Reading